Literature DB >> 17688268

Increased osteoblast adhesion on nanoparticulate calcium phosphates with higher Ca/P ratios.

Celaletdin Ergun1, Huinan Liu, Thomas J Webster, Ercan Olcay, Safak Yilmaz, Filiz C Sahin.   

Abstract

The biological properties of calcium phosphate-derived materials are strongly influenced by changes in Ca/P stoichiometry and grain size, which have not yet been fully elucidated to date. For this reason, the objective of this in vitro study was to understand osteoblast (bone forming cells) adhesion on nanoparticulate calcium phosphates of various Ca/P ratios. A group of calcium phosphates with Ca/P ratios between 0.5 and 2.5 were obtained by adjusting the Ca/P stoichiometry of the initial reactants necessary for calcium phosphate precipitation. For samples with 0.5 and 0.75 Ca/P ratios, tricalcium phosphate (TCP) and Ca(2)P(2)O(7) phases were observed. In contrast, for samples with 1.0 and 1.33 Ca/P ratios, the only stable phase was TCP. For samples with 1.5 Ca/P ratios, the TCP phase was dominant, however, small amounts of the hydroxyapatite (HA) phase started to appear. For samples with 1.6 Ca/P ratios, the HA phase was dominant. Last, for samples with 2.0 and 2.5 Ca/P ratios, the CaO phase started to appear in the HA phase, which was the dominant phase. Moreover, the average nanometer grain size, porosity (%), and the average pore size decreased in general with increasing Ca/P ratios. Most importantly, results demonstrated increased osteoblast adhesion on calcium phosphates with higher Ca/P ratios (up to 2.5). In this manner, this study provided evidence that Ca/P ratios should be maximized (up to 2.5) in nanoparticulate calcium phosphate formulations to increase osteoblast adhesion, a necessary step for subsequent osteoblast functions such as new bone deposition. Copyright 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17688268     DOI: 10.1002/jbm.a.31555

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  7 in total

1.  Effect of ceramic calcium-phosphorus ratio on chondrocyte-mediated biosynthesis and mineralization.

Authors:  Margaret K Boushell; Nora T Khanarian; Raquel Z LeGeros; Helen H Lu
Journal:  J Biomed Mater Res A       Date:  2017-06-21       Impact factor: 4.396

Review 2.  Biological properties of calcium phosphate biomaterials for bone repair: a review.

Authors:  Jingyi Lu; Huijun Yu; Chuanzhong Chen
Journal:  RSC Adv       Date:  2018-01-09       Impact factor: 4.036

Review 3.  Nanomaterials and synergistic low-intensity direct current (LIDC) stimulation technology for orthopedic implantable medical devices.

Authors:  Rohan A Shirwaiker; Meghan E Samberg; Paul H Cohen; Richard A Wysk; Nancy A Monteiro-Riviere
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-01-17

Review 4.  Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans.

Authors:  Pooja Arora; Annu Sindhu; Neeraj Dilbaghi; Ashok Chaudhury; Govindasamy Rajakumar; Abdul Abdul Rahuman
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

5.  Dissolution Behavior of Hydrothermally Treated Hydroxyapatite-Titanium Nitride Films Coated on PEEK: In Vitro Study.

Authors:  Siriwat Boonpok; Kwanchanok Koonrungsrisomboon; Kullapop Suttiat; Piriya Yavirach; Dhreerawan Boonyawan
Journal:  J Funct Biomater       Date:  2022-07-19

6.  Characteristics and in vitro response of thin hydroxyapatite-titania films produced by plasma electrolytic oxidation of Ti alloys in electrolytes with particle additions.

Authors:  W K Yeung; I V Sukhorukova; D V Shtansky; E A Levashov; I Y Zhitnyak; N A Gloushankova; P V Kiryukhantsev-Korneev; M I Petrzhik; A Matthews; A Yerokhin
Journal:  RSC Adv       Date:  2016-02-01       Impact factor: 3.361

7.  Bioactive effects of nonthermal argon-oxygen plasma on inorganic bovine bone surface.

Authors:  Chengzan Wu; Kai Ma; Hongmei Zhao; Qian Zhang; Yanshan Liu; Na Bai
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.